ALS Trials in Toronto, Canada
Conditions / ALS / Toronto, Canada
Research into ALS spans multiple therapeutic approaches and trial phases.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07193953 | Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) | RECRUITING | PHASE1 |
| NCT02405182 | MRI Biomarkers in ALS | COMPLETED | — |
| NCT05031351 | NF-κB Inhibition in Amyotrophic Lateral Sclerosis | UNKNOWN | PHASE2 |
| NCT00349622 | Clinical Trial Ceftriaxone in Subjects With ALS | COMPLETED | PHASE3 |
| NCT04569084 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED | PHASE3 |
| NCT04259255 | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) | UNKNOWN | — |
| NCT04948645 | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis | TERMINATED | PHASE1 |
| NCT04931862 | Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) | TERMINATED | PHASE1/PHASE2 |
| NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | TERMINATED | PHASE3 |
| NCT03272503 | A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) | UNKNOWN | PHASE2 |